Key facts
- • FDA approved Nov 2023 for chronic weight management — newer vs Wegovy (2021).
- • 22.5% mean weight loss at 15 mg (SURMOUNT-1) — highest of any FDA-approved weight-loss medication.
- • Cash list ~$1,086/mo — cheaper than Wegovy ($1,349).
- • LillyDirect vials ~$299/mo — direct-to-consumer cheaper option (manual injection).
- • Dual GIP+GLP-1 agonist — explains efficacy advantage vs semaglutide-only Wegovy.
Clinical evidence: SURMOUNT trials
SURMOUNT-1 trial: ~2,500 adults with obesity (BMI ≥30 or BMI ≥27 + comorbidity), 72 weeks. Mean weight loss at end of titration:
- 15 mg dose: 22.5% body weight loss (highest)
- 10 mg dose: 21.4%
- 5 mg dose: 16.0%
- Placebo: 2.4%
SURMOUNT-2 (T2D patients) showed 13.4-17.6% weight loss + glycemic control improvement. SURMOUNT-3 (intensive lifestyle pre-treatment) showed 18.4% additional loss after switching to tirzepatide.
Cost landscape
| Path | Cost |
|---|---|
| Cash list autoinjector pen | ~$1,086/mo |
| LillyDirect single-dose vial | $299–$699/mo |
| Commercial insurance copay | $25-100/mo typical |
| Compounded tirzepatide | $199-399/mo |
| Medicare | Not covered weight loss |
Dose schedule
- Weeks 1-4: 2.5 mg weekly — initiation
- Weeks 5-8: 5 mg weekly
- Weeks 9-12: 7.5 mg weekly
- Weeks 13-16: 10 mg weekly
- Weeks 17-20: 12.5 mg weekly
- Weeks 21+: 15 mg weekly — maximum dose
20-week titration, longer than Wegovy. Provider may hold at lower dose if response satisfactory or side effects.
LillyDirect vial vs pen tradeoff
Eli Lilly launched LillyDirect (online direct-to-consumer pharmacy) with single-dose vials from $299/mo at the starting dose — significantly cheaper than $1,086/mo autoinjector pen. Tradeoff:
- Pro: 67% cheaper cash vs pen format
- Pro: Available direct without telehealth provider
- Con: Vial requires user to draw correct dose with syringe + inject manually (vs autoinjector one-click)
- Con: No telehealth wrapper — patients self-manage refills + dose questions
- Con: Available only through LillyDirect, not third-party pharmacies
Zepbound vs Wegovy
| Factor | Zepbound | Wegovy |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Receptor mechanism | Dual GIP/GLP-1 | GLP-1 only |
| Max weight loss (trial) | 22.5% (SURMOUNT-1) | 14.9% (STEP-1) |
| Cash list (pen) | ~$1,086/mo | ~$1,349/mo |
| Direct vial option | Yes, $349/mo | No vial |
| FDA approved | Nov 2023 (newer) | June 2021 |
FAQ
How much weight do you lose on Zepbound?
SURMOUNT-1 trial: 22.5% mean body weight loss at 15 mg dose over 72 weeks (highest of any FDA-approved weight-loss medication). 36% achieved ≥25% loss. Significantly outperforms Wegovy (14.9% STEP-1). Dual-receptor agonist (GIP+GLP-1) explains improved efficacy vs semaglutide-only Wegovy.
What does Zepbound cost?
Cash list ~$1,086/mo (cheaper than Wegovy $1,349). LillyDirect single-dose vials ~$299/mo (significantly cheaper than autoinjector pens). With commercial insurance: copay $25-100/mo typical. Medicare typically not covers weight loss; Medicaid varies.
Zepbound vs Wegovy — which is better?
Zepbound more effective (22.5% vs 14.9% weight loss), cheaper cash list ($1,086 vs $1,349), but newer (FDA approved Nov 2023 vs Wegovy 2021). Side effect profile similar — both GLP-1 class. If insurance covers both, Zepbound usually preferred. Wegovy advantage: longer track record, more telehealth provider familiarity.
How is the LillyDirect vial cheaper?
Lilly launched single-dose vials (vs autoinjector pens) direct-to-consumer from $299/mo at the starting dose. Skips wholesale + pharmacy markup of pen format. Tradeoff: vial requires user to draw + inject manually (less convenient vs autoinjector). Available only via LillyDirect website, not traditional pharmacies.
Side effects?
Same GLP-1 class profile: nausea (~30-40%), diarrhea, constipation, vomiting, abdominal pain. Hypoglycemia in diabetes patients on insulin. FDA black-box thyroid warning. Pancreatitis, gallbladder disease rare.
Is compounded tirzepatide same as Zepbound?
Same molecule (tirzepatide) but different supply. Compounded tirzepatide is pharmacy-mixed, not FDA-approved as finished product. FDA ended tirzepatide compounding shortage status March 2025 — ongoing enforcement action against telehealth firms continuing to prescribe (Eden, Henry, SkinnyRx). Cheaper $199-399/mo but carries enforcement risk.
Best telehealth for Zepbound?
Ro Body (multi-drug brand formulary), LifeMD (cheapest insurance-friendly), Hers (Novo+Lilly partnership coverage). LillyDirect bypasses telehealth — direct-to-consumer model.
Bottom line
Zepbound is most effective + cheaper cash list vs Wegovy. LillyDirect vial ~$299/mo (manual injection) beats every telehealth-wrapped option on price. If insurance covers both Zepbound + Wegovy, Zepbound usually preferred. Compare providers.
Sources
Editorial only — not medical advice. Pricing accurate as of 2026-06-05.